Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPM001 in Hepatocellular Carcinoma After Surgical Resection
NCT05105815Phase 1Unknown
- Sponsor
- Huashan Hospital
- Start
- Dec 2021
- Primary completion
- Dec 2023
- Modality
- Prophylactic Vaccines, Cell Therapies, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IPM001 in hepatocellular carcinoma (HCC), sponsored by Huashan Hospital. Primary endpoint: Disease-Free Survival at 18 months. Status: unknown.
02
Drugs
IPM001
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05105815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05105815.